Theralase Technologies Inc. (CVE:TLT – Get Free Report) rose 17.9% during trading on Friday . The stock traded as high as C$0.23 and last traded at C$0.23. Approximately 714,214 shares traded hands during trading, an increase of 122% from the average daily volume of 321,276 shares. The stock had previously closed at C$0.20.
Theralase Technologies Price Performance
The stock has a 50 day moving average of C$0.17 and a two-hundred day moving average of C$0.19. The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The stock has a market cap of C$64.90 million, a PE ratio of -13.61 and a beta of -0.35.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Further Reading
- Five stocks we like better than Theralase Technologies
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- A U.S. “birthright” claim worth trillions – activated quietly
- Ticker Revealed: Pre-IPO Access to “Next Elon Musk” Company
- First Time Since 2007: All Warnings Active
- How the Rich Retire
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
